explore -WSS

explore

author：fashion 2025-09-29 01:36:50 - browse：7372

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Patient advocates debate FDA's accelerated approval process

WSS

Retired US general questions alleged Putin, Prigozhin meeting

Study says nonprofit hospitals fall short in charity care spending

Readout Newsletter: Merck, Vertex, and Viking updates

There's no autism epidemic. It's an autism diagnosis epidemic

Lecanemab for Alzheimer's is coming. Is the health system ready?

Oprah kicked off a national conversation on obesity. Let's have it

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

In Memoriam: Notable people who died in 2023

Decaf coffee targeted by food safety group under obscure FDA rule

Supreme Court strikes down use of affirmative action

Steward Health Care has deal to sell doctor network to UnitedHealth

Affirmative action in medical school literally saved lives

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Supreme Court strikes down use of affirmative action

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Food as medicine: Medically tailored meals may get standardized

entertainment

Leqembi, other new Alzheimer’s drugs require better biomarkers

Eliminate the waiting period for sterilization covered by Medicaid

Abortion pill Supreme Court ruling could impact entire drug industry

Palantir health business leans on meeting customers’ needs

Vertex Pharmaceuticals may move headquarters in Boston

Iowa House, Senate pass 6

knowledge

hotspot

hotspot

hotspot